Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis

  • Georg Greiner
    Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
  • Michael Gurbisz
    Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
  • Franz Ratzinger
    Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
  • Nadine Witzeneder
    Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
  • Ingrid Simonitsch-Klupp
    Department of Pathology, Medical University of Vienna, Vienna, Austria
  • Gerlinde Mitterbauer-Hohendanner
    Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
  • Matthias Mayerhofer
    Ludwig Boltzmann Institute of Osteology, Hanusch Hospital, Vienna, Austria
  • Leonhard Müllauer
    Department of Pathology, Medical University of Vienna, Vienna, Austria
  • Wolfgang R Sperr
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
  • Peter Valent
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
  • Gregor Hoermann
    Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria

説明

<jats:title>Abstract</jats:title> <jats:sec> <jats:title>BACKGROUND</jats:title> <jats:p>The analytically sensitive detection of KIT D816V in blood and bone marrow is important for diagnosing systemic mastocytosis (SM). Additionally, precise quantification of the KIT D816V variant allele fraction (VAF) is relevant clinically because it helps to predict multilineage involvement and prognosis in cases of advanced SM. Digital PCR (dPCR) is a promising new method for sensitive detection and accurate quantification of somatic mutations.</jats:p> </jats:sec> <jats:sec> <jats:title>METHODS</jats:title> <jats:p>We performed a validation study of dPCR for KIT D816V on 302 peripheral blood and bone marrow samples from 156 patients with mastocytosis for comparison with melting curve analysis after peptide nucleic acid-mediated PCR clamping (clamp-PCR) and allele-specific quantitative real-time PCR (qPCR).</jats:p> </jats:sec> <jats:sec> <jats:title>RESULTS</jats:title> <jats:p>dPCR showed a limit of detection of 0.01% VAF with a mean CV of 8.5% and identified the mutation in 90% of patients compared with 70% for clamp-PCR (P &lt; 0.001). Moreover, dPCR for KIT D816V was highly concordant with qPCR without systematic deviation of results, and confirmed the clinical value of KIT D816V VAF measurements. Thus, patients with advanced SM showed a significantly higher KIT D816V VAF (median, 2.43%) compared with patients with indolent SM (median, 0.14%; P &lt; 0.001). Moreover, dPCR confirmed the prognostic significance of a high KIT D816V VAF regarding survival (P &lt; 0.001).</jats:p> </jats:sec> <jats:sec> <jats:title>CONCLUSIONS</jats:title> <jats:p>dPCR for KIT D816V provides a high degree of precision and sensitivity combined with the potential for interlaboratory standardization, which is crucial for the implementation of KIT D816V allele burden measurement. Thus, dPCR is suitable as a new method for KIT D816V testing in patients with mastocytosis.</jats:p> </jats:sec>

収録刊行物

  • Clinical Chemistry

    Clinical Chemistry 64 (3), 547-555, 2018-03-01

    Oxford University Press (OUP)

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ